Quick answer
What is the chemical structure of melanotan II (MT-2)? A cyclic heptapeptide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, derived from the 13-residue hormone alpha-MSH. Four changes from the native sequence define it: an N-terminal acetyl group, norleucine in place of methionine, a D-phenylalanine in place of the L-form, and a lactam bridge joining the aspartic acid and lysine side chains that closes the ring. The MT-2 product page lists the formula as C50H69N15O9, which corresponds to a molar mass of about 1,024 g/mol when calculated from the formula. This article explains each change, how such a ring is assembled by solid-phase synthesis, and which impurities a chemist would expect. For laboratory research use only; the melanotan II research overview covers the wider context.
Melanotan II is usually discussed through its receptor pharmacology, but its identity is chemical: a small ring with deliberate substitutions that make it more stable and more potent than the hormone it imitates. This page is a structural and synthetic walk-through for researchers who want to understand what is in the vial and why it behaves as it does in solution. It is not a synthesis recipe. The material is supplied for laboratory research use only; not for human consumption.
From alpha-MSH to a cyclic heptapeptide
Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-residue peptide that darkens frog skin by stimulating melanosome movement within melanophores. In 1980, Sawyer and colleagues reported that heat-alkali exposure prolonged its biological activity and that this correlated with partial racemization at the methionine-4 and phenylalanine-7 positions. They synthesized [Nle4, D-Phe7]-alpha-MSH, which reproduced the prolonged activity, resisted degradation by serum enzymes, and was 26 times as potent as alpha-MSH in an adenylate cyclase assay (Sawyer et al., 1980). That analog, often called NDP-MSH, is the direct ancestor of the melanotan family.
Al-Obeidi and colleagues then described the design of a new class of superpotent cyclic alpha-melanotropins based on quenched dynamics simulations (Al-Obeidi et al., 1989). The title records the approach: computational conformational analysis guided the choice of a ring. Melanotan II belongs to the cyclic melanotropin family that grew out of this line of work. Our melanotan II purity testing and melanotan I pages cover its neighbors.
The table lines up the native hormone and the analog so each substitution can be traced.
| Feature | Alpha-MSH (native) | Melanotan II (MT-2) | Chemical consequence |
|---|---|---|---|
| Length | 13 residues, linear | 7 residues in a ring | Smaller, conformationally restricted |
| Position 4 | Methionine | Norleucine (Nle) | Same size, no oxidizable sulfur |
| Position 7 | L-phenylalanine | D-phenylalanine | Protease resistance; shapes the turn |
| Positions 5 and 10 | Glutamic acid and glycine in the linear sequence | Aspartic acid and lysine joined by a lactam bridge | Ring closure |
| Termini | Acetylated N-terminus, amidated C-terminus | Acetylated N-terminus, amidated C-terminus | No free terminal charges |
| Formula (product page) | Not applicable | C50H69N15O9 | Mass about 1,024 g/mol calculated |
Reading the sequence
The sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 reads as follows. Ac is the N-terminal acetyl cap. Nle is norleucine, an unbranched four-carbon side chain that is isosteric with methionine but lacks the thioether sulfur. The bracketed section is the ring: aspartic acid, histidine, D-phenylalanine, arginine, tryptophan and lysine, closed by an amide (lactam) bond between the aspartic acid side-chain carboxyl and the lysine side-chain amine. NH2 is the C-terminal amide.
The central tetrapeptide His-Phe-Arg-Trp is the segment shared with alpha-MSH, and it is the portion that melanocortin receptor binding studies regard as the message sequence. The cyclic design fixes these residues in a defined spatial arrangement. Because the ring is built from side chains, the backbone remains a normal peptide chain, and the molecule has no free N-terminal amine or C-terminal carboxylate, which affects its charge behavior in solution.
The product page lists the same sequence, the formula C50H69N15O9, a 10 mg size, at least 98% purity by HPLC and lyophilized powder supplied in a sealed clear glass research vial. It states storage at 2–8 °C, or −20 °C for long term, protected from heat, moisture and light. A COA is marked as coming soon, so a lab that needs batch documentation should check the page before relying on it.
Why each substitution exists
Norleucine for methionine. Methionine is among the residues most prone to oxidation, with the others including cysteine, histidine, tryptophan and tyrosine (Li et al., 1995). Replacing it with norleucine keeps the side-chain length and hydrophobicity while removing the sulfur that oxidizes. Sawyer and colleagues' observation that [Nle4]-alpha-MSH retained the activity of the native hormone and showed prolonged activity after heat-alkali exposure fits this logic (Sawyer et al., 1980).
D-phenylalanine at position 7. Natural proteases recognize L-amino acids, so a D-residue in the sequence reduces cleavage. The 1980 report found that the Nle4, D-Phe7 analog resisted enzymatic degradation by serum enzymes and showed dramatically increased biological activity in frog-skin, adenylate cyclase and tyrosinase assays (Sawyer et al., 1980).
The lactam ring. Cyclization restricts the conformations the peptide can adopt. For a short peptide in solution, flexibility means that only a small fraction of molecules adopt the receptor-binding shape at any moment; a ring raises that fraction. The 1989 design paper's use of dynamics simulations reflects this conformational reasoning (Al-Obeidi et al., 1989). The abstract of the 1980 paper does not describe the lactam, so the contribution of cyclization is attributed here to the later design work only by its title.
How such a ring is made: solid-phase synthesis in outline
Peptide chains of this kind are assembled on a solid support. Merrifield's 1963 paper on the synthesis of a tetrapeptide introduced the approach in which the C-terminal residue is anchored to an insoluble resin and the chain is lengthened one protected residue at a time, with excess reagents and by-products removed by washing (Merrifield, 1963). Modern practice follows the same logic with refined protecting groups and coupling reagents.
A lactam-cyclized peptide adds one conceptual requirement: the aspartic acid and lysine side chains must be protected with groups that can be removed selectively, while the other side chains stay protected. After chain assembly, the two groups are removed on the resin, an amide bond is formed between the freed carboxyl and amine, and then the remaining side chains are deprotected as the peptide is cleaved from the support. N-terminal acetylation and a C-terminal amide (from the choice of resin linker) complete the structure. This page deliberately does not give reagents or conditions.
The stage at which things go wrong is predictable, and each failure leaves a recognizable impurity, as summarized below.
| Synthesis step | Possible by-product | How it would show up analytically |
|---|---|---|
| Incomplete coupling | Deletion peptides lacking one residue | Earlier-eluting peak with lower mass |
| Racemization during activation | Diastereomers (for example L-Phe in place of D-Phe) | Closely eluting peak with the same mass |
| Intermolecular lactam formation | Dimers and oligomers | Later-eluting peak with roughly double mass |
| Incomplete ring closure | Linear precursor | Mass higher by one water |
| Incomplete deprotection | Peptide carrying a protecting group | Higher mass; often later-eluting |
| Tryptophan modification during cleavage | Oxidized or alkylated Trp species | Mass shifts such as plus 16 Da |
What this means for analysis and handling
A single chromatographic purity figure cannot tell diastereomers, dimers and the target apart unless the method resolves them. That is why identity (mass) and purity (area percent) are separate attributes; the comparison is explained in HPLC versus mass spectrometry and understanding HPLC purity. Because the product page states HPLC purity and does not describe other methods, this page makes no claim about additional analyses.
For handling, the structure predicts three things. First, the D-residue was shown in the 1980 analog to resist serum enzymes, but chemical routes remain regardless: oxidation of the tryptophan and slow hydrolysis. Second, the cap and amide termini mean the molecule has no terminal charges, which changes its solubility and chromatographic retention from a free-terminus peptide. Third, as a dry solid the peptide is best kept cold and dry, since solid-state proteins can still have limited long-term storage stability even after lyophilization (Wang, 2000; Manning et al., 2010). The step-by-step handling is on how to reconstitute a lyophilized peptide, the arithmetic in peptide reconstitution volume calculations, and a calculator is at /calculator.
Putting the structure to use in the lab
Knowing the structure is practical. It lets a researcher compute the molar mass from the formula for concentration work, predict which residues are likely to limit stability (tryptophan and histidine here, with methionine absent), choose analytical conditions that separate likely impurities, and select appropriate negative controls such as a linear or scrambled analog. For receptor-level context, the compound sits in the melanocortin family, whose receptors were cloned in the early 1990s (Mountjoy et al., 1992) and whose physiology is reviewed by Cone (2006). A comparison with another melanocortin analog is on the PT-141 versus melanotan II page.
Documentation closes the loop: record the lot, check the COA where one is published, and keep the storage log. The full catalog is on the shop.
Frequently asked questions
What is the structure of melanotan II?
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, a cyclic heptapeptide closed by a lactam bridge between the aspartic acid and lysine side chains.
What is its molecular formula?
C50H69N15O9 per the product page, corresponding to a molar mass of about 1,024 g/mol calculated from the formula.
What is norleucine and why is it used?
An unbranched amino acid similar in size to methionine but without sulfur, which removes the thioether that oxidizes readily (Li et al., 1995).
Why does the sequence contain a D-amino acid?
D-phenylalanine at position 7 was part of the analog that resisted degradation by serum enzymes and showed greatly increased activity in 1980 assays (Sawyer et al., 1980).
What is a lactam bridge?
An amide bond formed between a side-chain carboxyl (here aspartic acid) and a side-chain amine (here lysine) that closes the ring.
Is melanotan II a hormone?
No. It is a synthetic analog derived from the sequence of alpha-MSH.
How are such peptides made?
By solid-phase synthesis, introduced in 1963 (Merrifield, 1963), with selective side-chain protection to allow on-resin ring closure.
What impurities are expected?
Deletion peptides, diastereomers, dimers, the linear precursor, incompletely deprotected species and tryptophan-modified forms.
Can HPLC alone identify these impurities?
Only if the method resolves them. Mass information is needed to assign identity, which is why identity and purity are separate attributes.
How should the vial be stored?
As stated on the product page: refrigerate at 2–8 °C, or −20 °C for long-term holding, protected from heat, moisture and light.
Responsible research use
Everything on this page is offered for laboratory research use only; it is background reading for qualified researchers, not guidance for any use outside a research setting, and nothing here is a claim about benefit in people or animals. Products from V8 Peptides are sold strictly as research materials: not a drug, food or cosmetic, and not for human or animal consumption. Published studies described here were run by their authors under their own approvals and protocols, and this page does not recommend repeating them.
Related reading: Melanotan II History: From alpha-MSH to Receptor Cloning, Melanotan II Mechanism: Receptor Binding and cAMP Assays, Reconstituted Melanotan II Stability: Study Design.
References
- Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77(10):5754-5758. doi:10.1073/pnas.77.10.5754
- Al-Obeidi F, Hadley ME, Pettitt BM, Hruby VJ. Design of a new class of superpotent cyclic alpha-melanotropins based on quenched dynamics simulations. J Am Chem Soc. 1989;111(9):3413-3416. doi:10.1021/ja00191a044
- Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. doi:10.1021/ja00897a025
- Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490-500. doi:10.1002/bit.260480511
- Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203(1-2):1-60. doi:10.1016/S0378-5173(00)00423-3
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science. 1992;257(5074):1248-1251. doi:10.1126/science.1325670
- Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736-749. doi:10.1210/er.2006-0034
